x
Filter:
Filters applied
- EMAS Position Statements and Clinical Guides
- Breast cancerRemove Breast cancer filter
Publication Date
Please choose a date range between 2014 and 2022.
Author
- Ceausu, Iuliana3
- Lambrinoudaki, Irene3
- Rees, Margaret3
- Depypere, Herman2
- Mueck, Alfred2
- Pérez-López, Faustino R2
- Simoncini, Tommaso2
- Stute, Petra2
- van der Schouw, Yvonne T2
- Armeni, Eleni1
- Bretz, Silvia1
- Desreux, Joelle1
- Durmusoglu, Fatih1
- Erel, C Tamer1
- Erkkola, Risto1
- Fistonic, Ivan1
- Gambacciani, Marco1
- Geukes, Marije1
- Goulis, Dimitrios1
- Hamoda, Haitham1
- Hartley, Caiomhe1
- Hirschberg, Angelica Lindén1
- Meczekalski, Blazej1
- Mendoza, Nicolas1
- Schenck-Gustafsson, Karin1
EMAS Position Statements and Clincial Guides
3 Results
- EMAS Consensus Statement
Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society
MaturitasVol. 163p1–14Published online: May 12, 2022- Irene Lambrinoudaki
- Eleni Armeni
- Dimitrios Goulis
- Silvia Bretz
- Iuliana Ceausu
- Fatih Durmusoglu
- and others
Cited in Scopus: 10Life expectancy has considerably increased since 1970 [1], and now >50% of women are expected to break the 90-year barrier by 2030 [2]. Growing older rather than old means spending almost half of life after the menopause, challenging the concept of healthy ageing [3]. Iatrogenic menopause may be induced by cancer treatment or bilateral salpingo-oophorectomy for benign disease and may occur before the average age of natural menopause, which is around the age of 50 [4,5]. The sudden fall in estrogen levels with iatrogenic menopause may lead to rapid onset of vasomotor symptoms [4]. - Review article
Osteoporosis management in patients with breast cancer: EMAS position statement
MaturitasVol. 95p65–71Published online: October 6, 2016- Florence A. Trémollieres
- Iuliana Ceausu
- Herman Depypere
- Irene Lambrinoudaki
- Alfred Mueck
- Faustino R. Pérez-López
- and others
Cited in Scopus: 33Breast cancer remains the most frequent cancer in women and its incidence is increasing. However, the mortality rate has stabilized due to the progress made in the treatment of breast cancer over the last decade. In premenopausal women with hormone receptor-positive breast cancer, the goal of adjuvant treatment is to inhibit the impact of estrogen on the breast, either by blocking the estrogen receptors (with the use of tamoxifen) or by suppressing ovarian function (through surgical oophorectomy or treatment with luteinizing hormone-releasing hormone (LHRH) agonist). - Research Article
EMAS position statement: Individualized breast cancer screening versus population-based mammography screening programmes
MaturitasVol. 79Issue 4p481–486Published online: September 14, 2014- Herman Depypere
- Joelle Desreux
- Faustino R. Pérez-López
- Iuliana Ceausu
- C. Tamer Erel
- Irene Lambrinoudaki
- and others
Cited in Scopus: 19Breast cancer originates from the malignant transformation of epithelial cells within the ducts and lobules of the breast. A malignant cell is the result of the accumulation of consecutive mutations. Up or down regulation of different mutated genes will ultimately result in the heterogeneity of breast cancers [1]. Some tumors will remain in situ and will never threaten the health of women. Other tumors will become invasive and ultimately metastasize and hence be fatal when not treated. The doubling time of tumor cells is estimated between 150 and 200 days [2].